QUÉBEC
FIRAZYR is covered by the Régie de l’assurance maladie du Québec (RAMQ) (Special Authorization)
Eligibility
FIRAZYR is considered an “exceptional medication” in the List of Medications. To be covered, prescribers must submit an authorization request to RAMQ† and the request must be approved before the prescription will be covered. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.
Reimbursement Criteria
We are pleased to inform you that FIRAZYR (icatibant acetate) is reimbursed in Québec for your hereditary angioedema (HAE) patients who meet the following criteria:
Pour le traitement des crises aigües d’angio-oedème héréditaire (AOH) causées par un déficit en inhibiteur de la C1 estérase chez les adultes :
- dont le diagnostic d’AOH de type I ou type II a été confirmé par un dosage antigénique ou un dosage fonctionnel de l’inhibiteur de la C1 estérase inférieur aux valeurs normales, ET
- ayant subi au moins une crise aigüe d’AOH confirmée médicalement
Les autorisations seront données pour un maximum de 12 seringues d’icatibant par période de 12 mois.
For treatment of acute attacks of HAE with C1-esterase inhibitor deficiency in adults:
- whose diagnosis of HAE type I or type II was confirmed by an antigen dosage or a functional dosage of the C1-esterase inhibitor below the lower limit of normal, AND
- having suffered at least one medically-confirmed acute attack of HAE
Authorizations will be given for a maximum of twelve syringes of icatibant per 12-month period.
OnePath® Patient Support Program will help navigate insurance coverage and access reimbursement to medication through private and public insurance companies.
† Official Mark of the Régie de l’assurance maladie du Québec.
Source: RAMQ List of Medications. March 2022.
https://ramqinter.prod.acquia-sites.com/sites/default/files/documents/liste_med_2022-03-02_en.pdf